Connect with us

BUSINESS

MedReleaf And Aurora Cannabis Inc (OTCMKTS:ACBFF) Close One Of The Biggest Cannabis Transactions Globally

Published

on

The arrangement agreement between Aurora Cannabis Inc (OTCMKTS:ACBFF) and MedReleaf Corp has finally come to a close. The terms of the agreement were well stipulated. For each common share of MedReleaf, 3.575 common shares of Aurora were given out.

A close outlook into the matter

Aurora is expected to submit its applications with the Toronto Stock Exchange immediately upon the close of the transaction. It will also be submitting them to the Ontario Securities Commission, a move that will see to it that MedReleaf’s existing common shares get delisted. The other thing is that MedReleaf will no longer be a reporting issuer.

The current CEO of Aurora is called Terry Booth and has he has been supporting the close of this transaction a great deal. He sees it as a way to merge two successful pioneers in the fast growing cannabis sector. Hopefully, we might soon be witnessing a company with the capacity to employ over 1,200 people. It will be swift at establishing its global footprint in a bid to give a major lift to its revenue streams.

He opined, “The combination of MedReleaf and Aurora creates a well capitalized company positioned exceptionally well to generate further shareholder value, driven by the low-cost production of high-quality cannabis products.”

Progress made so far and future expectations

There are plans underway to apply the company’s trusted integration methodology in a bid to survive in a market characterized by stiff competition. There are plans to make the most out of the great opportunities in both global and domestic cannabis industry.

Mr. Booth is looking forward to a bright future where they will have a thriving and strongly differentiated cannabis company. He promises that they will be channeling much of their resources and efforts in helping it achieve rapid growth.

The Canadian and global cannabis markets are currently experiencing major transformations. The legalization of cannaibis in several states is a major change. Very few imagined that we would soon get to the point where Cannabis would become a common household name. There are a wide range of health benefits linked to these products. They are growing popular globally with every passing day.

BUSINESS

Elev8 Brands (OTCMKTS:VATE) Partners With Linda Bos To Promote The Use Of CBD Infused Creams And Beverages To Improve Health Of Athletes

Published

on

Elev8 Brands (OTCMKTS:VATE) has partnered with Linda Bos of Outwest 505 Distributing and arena soccer team – the New Mexico Runners to promote the use of CBD infused products for athletes. The company is offering CBD infused products, including beverages and creams, for athletes to improve their health and overall performance.

Several professional athletes endorse CBD use

Several former and current athletes engaged in various sports are supporting the use of CBD. President and team owner of the New Mexico Runners, which is based in Rio Rancho, New Mexico, – Andres Trujillo, said CBD boosts energy and improves alertness. CBD also encourages athletes to run faster and recover faster. He said partnering with Linda Bos and Elev8 helps to provide athletes with high-quality CBD to improve their performance and feel better. It is on the backdrop of the kickstart of the second professional area soccer team season by the New Mexico Runners in the Major Arena Soccer League 2. As a result, Elev8 improves its footprint in New Mexico. It also establishes the footprint in Arizona.

Sales of Elev8 beverages surge

Linda Bos said the sales of Elev8 beverages and CBD are surging because of their focus on CBD and hemp benefits. It is noted that local customers are purchasing at a time up to four ready to drink teas. As a result, the sales of ready to drink teas surged to four cases a week from one 12-pack case in a week. Linda said to cater to the growing demand; she ordered five pallets. On completing the geo expansion, the monthly orders will increase to eight pallets. The growth is exciting, with increased demand for CBD and beverages from retailers in Arizona and New Mexico.

10.94 mg of CBD in ready-to-drink iced teas

Elev8 said the lab results show the presence of 10.94 mg of CBD in ready to drink iced teas (in each bottle). The tests upheld the accuracy and consistency of its products. Elev8 is striving to offer the best to its valued consumers. The market for CBD infused beverages would reach $1.25 billion by the year 2024. CBD products offer wellness and health benefits.

Continue Reading

BUSINESS

A Look Back At A Long List Of Accomplishments Of Neutra Corp (OTCMKTS:NTRR) In 2019: Neutra Continues To Thrive n 2020

Published

on

Neutra Corp (OTCMKTS:NTRR) acquired VIVIS in September 2019. VIVIS has introduced transdermal skin cream, which is derived from hemp. The takeover of VIVIS helped the company to support its yearning for the development and sale of hemp-based CBD products that include skin creams for sports enthusiasts and athletes. It also helped the company to establish its footprint in the surging CBD market. The users can confidently use third-party certified CBD products for health and wellness benefits. The CBD products of Neutra are free from contamination and offer consistent potency.

Cancelled reverse split

Neutra has canceled the proposed reverse split on the backdrop of positive sentiment from the market for the takeover of VIVIS and positive progress. The company also signed an LOI to jointly develop a myriad of hemp-based medicinal products to meet the growing demand for CBD. According to some analysts, the market for CBD is expected to reach $11 billion by the year 2026.

Rights to hemp trademark

Neutra will get access to the research findings to use CBD as neutral protectants and antioxidants on completion of the accord with Orgaceutical Co, based in Harrisburg, PA. The company will also receive rights to centrally licensed hemp trademark. Neutra will also receive the Commonwealth of Pennsylvania’s Department of Agriculture issued hemp cultivation license.

Chief Executive Officer of Neutra, Sydney Jim said the LOI helps the company to proceed with R&D to develop exciting applications for medicinal CBD products derived from hemp. The cultivation license allows the company to ensure a consistent supply of high-quality hemp.

Hires Dr. Scott E. Cherry, DO, MPH

Neutra has hired Dr. Scott E. Cherry to gain from the sports performance market. Scott contributes significant experience in healthcare facilities and Fortune 500 companies.

As part of its growth and expansion efforts, Neutra entered an LOI with Power Auto Corporation to take over a complex that comprises land and buildings. Neutra would use the new facility to accomplish its vertical integration dreams. Commenting on the deal, Jim said the new facility allows the company to supply the market with high quality and consistent products.

After achieving significant progress in 2019, Neutra plans to maintain the same growth prospects in 2020.

Continue Reading

BUSINESS

Pharmacyte Biotech Inc (OTCMKTS:PMCB) Addresses Unmet Medical Needs Of Patients Suffering From LAPC: 57,600 People In The US Suffers From LAPC In 2020

Published

on

Pharmacyte Biotech Inc (OTCMKTS:PMCB) is moving ahead with its proposed Phase 2b clinical trial in patients suffering from locally advanced, inoperable pancreatic cancer (LAPC). The company will conduct the clinical trial in patients, who no longer see any improvement after the treatment for 4 to 6 months using the first-line therapies. According to a communiqué from the American Cancer Society, the five-year survival rate for patients with LAPC has increased to 10%, an increase of 1%. Certainly, it is good news for patients suffering from LAPC.

Working together to treat LAPC

The entire community comprising pancreatic cancer researchers, volunteers, healthcare professionals, and other advocates are working together to achieve progress in LAPC in 2020. Chief Executive Officer (Pancreatic Action Network) and President of Pharmacyte, Julie Fishman, said he is grateful for the diligent efforts put in by the entire community of professionals and researchers to achieve progress in curing LAPC.

47,050 pancreatic cancer patients to die in 2020

Pancreatic cancer, which is the 3rd leading cause of cancer-associated deaths, ranks 11th in the US among the most diagnosed cancers. According to the estimates, 57,600 people in the US are expected to get diagnosed with pancreatic cancer this year. Around 47,050 people suffering from LAPC in the US are expected to die in 2020.

Therefore, the above facts are alarming and need funds and urgent attention on continued research to find a promising therapy. As part of this action, Pharmacyte is gearing to administer its Cell-in-a-Box, a signature live-cell encapsulation technology, together with lower dosages of ifosfamide, an anticancer drug, to patients suffering from LAPC.

At present, patients diagnosed with late-stage pancreatic cancer are treated using first-line chemotherapy such as folfirinox or Abraxane and Gemcitabine. If the patients are not receiving any benefits after administering these medicines, their hopes are fading for any meaningful cure.

Pharmacyte strives to make a change

Pharmacyte is putting in considerable efforts to achieve a breakthrough in treatment for patients suffering from LAPC. The company uses cellular targeted chemotherapy to turn the inoperable tumors into operable and remove them through surgery. However, it is only possible if pancreatic cancer is not spread to other parts of the body.

Pharmacyte said its two batches of the clinical trial product have successfully passed the 7 out of 10 release tests. Kenneth L. Waggoner, the CEO, said the clinical trial products are performing satisfactorily in the release test. The data collected from these tests helps the company to apply for FDA nod for the investigational drug to cure LAPC.

Continue Reading



Trending Stories